Skip to main content
OpenTrials
Completed

NCT Number: NCT01529099

Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM

This is a postmarketing study to assess the overall performance and survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Orthopedic Institute IRCCS Galeazzi, Milan, Italy

Loading trial locations.

About this study

The purpose of this study is to collect more information about the Sigma HP® Partial Knee System made by DePuy International. The aim of this study is to measure how this particular type of knee replacement performs over a two year period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects, aged at least 21 years.
  • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
  • Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
  • Subject has non-inflammatory degenerative joint disease (NIDJD), including: osteoarthritis, posttraumatic arthritis, avascular necrosis and chondrocalcinosis.
  • Subject has a functional stable knee.
  • Subject, in the opinion of the Investigator, is suitable for either a single or bicompartmental knee replacement.
  • Subject meets the following selected radiographic parameters:
  • X-ray evaluation confirms the presence of NIDJD
  • Disease location: 1 to 2 compartments, maximum. Disease can be present in the patellofemoral compartment, the medial tibiofemoral compartment, lateral tibiofemoral compartments alone or in any two compartments.
  • Disease severity: Kellgren and Lawrence44 Grade II or greater for all compartments replaced.

Exclusion criteria

  • Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
  • Women who are pregnant.
  • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
  • Subjects who have participated in a clinical investigation with an investigational product in the last 3 months.
  • Subjects who are currently involved in any injury litigation claims.
  • Multiple joint involvement that will compromise rehabilitation (for example: advanced hip, ankle or spine disease).
  • Known to be a prisoner, mentally incompetent, an alcohol / drug abuser, involved in medical-legal case or worker's compensation
  • Previous knee arthroplasty (any type) in any one of the three compartments of the knee.
  • Requires more than a lateral soft tissue release or an anterior cruciate ligament reconstruction.
  • Uncorrectable anatomical tibio-femoral angle.
  • Bone deficiency requiring structural bone grafts to support the implants.
  • Previous patellectomy.
  • For Subjects indicated for a patellofemoral arthroplasty, Subject has uncorrected patella baja (Caton-Deschamps ratio less than or equal to 0.6).
  • Tri-compartmental disease process (patella-femoral, medial tibio-femoral and lateral tibio-femoral).
  • Active bacterial infection that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of knee joint, urinary tract infection, etc.).
  • Significant neurological or musculoskeletal deformity or a disease that may affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis, amputation).
  • Known allergy to implant materials.

Treatment and study plan

SIGMA HP PARTIAL KNEE

Device

SIGMA HP PARTIAL KNEE

Other names: Sigma HP Partial Knee Femoral component, Sigma HP Partial Knee Tibial component, Sigma HP Partial Knee Tibial insert component, Sigma Patellae, Sigma HP Partial Knee Trochlear component

Primary outcomes

  1. Survivorship (revision)

    Time frame: 2 years

    Kaplan Meier Survival analysis at 2 years (based on revision of the femoral or tibial components)

Other outcomes

  1. Types and Frequency of Adverse Events

    Time frame: Throughout the study

  2. Clinical outcome using the AKS score

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

  3. Patient-reported outcome using the KOOS assessment

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

  4. Patient-reported outcome using the HAAS assessment

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

  5. Patient-reported outcome using the Kujala score

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

  6. Patient-reported outcome using the Oxford Knee Score

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

  7. Patient-reported outcome using the EQ-5D assessment

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

  8. Radiographic assessment

    Time frame: 6 weeks, 6 months, 1 year and 2 years post-op

Sponsors and collaborators

Lead sponsor

DePuy International

Industry

Registry information

Official study title

A Prospective, Non-comparative, Single Centre Study to Determine the Performance & Survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM.

Important dates

Study start
2009
Primary completion
2015
Study completion
2015
First posted
Feb 8, 2012
Registry last updated
May 30, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.